Therapeutic and prognostic significance of indoleamine 2, 3-dioxygenase (IDO) in he-matologic malignancy
10.3969/j.issn.1000-8179.2018.08.419
- VernacularTitle:吲哚胺-23-双加氧酶对血液系统肿瘤治疗与预后的意义
- Author:
Dongwei WU
1
;
Lin WU
;
Bing XIA
Author Information
1. 天津医科大学肿瘤医院血液科
- Keywords:
IDO;
immunosuppression;
hematological malignancy;
treatment;
prognosis
- From:
Chinese Journal of Clinical Oncology
2018;45(8):413-417
- CountryChina
- Language:Chinese
-
Abstract:
The defense mechanism of tumor immune response is triggered spontaneously with the onset of oncogenesis in hemato-logical malignancy. However, the presence of activated immune cells and effector cytokines activates multiple immunosuppressive pathways prior to clinical diagnosis of tumors,which synergize with each other and cause dysfunction of tumor antigen-specific T cells, ultimately leading to a state of immune tolerance in hematological malignancies.Indoleamine-2,3-dioxygenase(IDO)is an important member of these immunosuppressive pathways,which induces counter-regulation to limit the inflammatory response and triggers T cell-acquired tolerance,eventually inhibiting the tumor immune response.Considering the role of IDO in immunosuppression,IDO in-hibitors constitute an important part of the immunotherapeutic arsenal against various tumors,especially hematological malignancies, and have been studied extensively in recent years.This review discusses the significance of IDO and its inhibitors in the treatment and prognosis of hematological malignancies.
